GPO Prepares 200,000 Bird Flu Vaccines

Production to Begin in March Ahead of Potential Outbreak

The Government Pharmaceutical Organisation (GPO) is gearing up to produce 200,000 doses of a bird flu vaccine in March, anticipating a possible outbreak in June.

GPO Director Mingkwan Suphanpong stated that the production will use the H5N2 strain and employ egg-based vaccine technology. The first batch is expected to be available by May, with a shelf life ranging from six months to two years. The GPO has the capacity to increase production to 500,000 doses if necessary.

This initiative follows rising global concern over bird flu cases reported in nations like the United States, the United Kingdom, and neighboring countries. The World Health Organization (WHO) has urged member states to monitor and report outbreaks closely.

The vaccine will be suitable for individuals aged 18 and above. The Department of Disease Control (DDC) will prioritize vaccination for high-risk groups, including poultry farmers and residents in vulnerable areas.

Dr. Mingkwan noted that outbreaks could coincide with the rainy season in June. If mutations occur, the GPO can quickly adjust production to accommodate new strains, using starter strains supplied by the WHO.

Meanwhile, Dr. Panumas Yanwateesakul, head of the DDC, assured that the department is closely monitoring the situation. It is coordinating with the Department of Medical Services to ensure adequate stocks of oseltamivir and other influenza treatments are available.